1941 related articles for article (PubMed ID: 22716221)
1. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
2. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
4. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
5. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W
Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Qaseem A; Forciea MA; McLean RM; Denberg TD; ; Barry MJ; Cooke M; Fitterman N; Harris RP; Humphrey LL; Kansagara D; McLean RM; Mir TP; Schünemann HJ
Ann Intern Med; 2017 Jun; 166(11):818-839. PubMed ID: 28492856
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
9. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
10. The clinician's guide to prevention and treatment of osteoporosis.
LeBoff MS; Greenspan SL; Insogna KL; Lewiecki EM; Saag KG; Singer AJ; Siris ES
Osteoporos Int; 2022 Oct; 33(10):2049-2102. PubMed ID: 35478046
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
12. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Peterson J; Zheng C; Kelly SE; Shea B; Tugwell P
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD003376. PubMed ID: 38591743
[TBL] [Abstract][Full Text] [Related]
13. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
15. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of vitamin D in relation to bone health.
Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
[TBL] [Abstract][Full Text] [Related]
17. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]